Production (Stage)
Protagenic Therapeutics, Inc.
PTIX
$3.62
$0.1353.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 104.50% | 268.43% | -6.43% | 47.46% | -29.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.70% | 35.56% | -54.45% | 45.78% | 135.14% |
| Operating Income | 16.70% | -35.56% | 54.45% | -45.78% | -135.14% |
| Income Before Tax | 16.49% | 7.31% | 54.12% | -32.81% | -140.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.49% | 7.31% | 54.12% | -32.81% | -140.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.49% | 7.31% | 54.12% | -32.81% | -140.12% |
| EBIT | 16.70% | -35.56% | 54.45% | -45.78% | -135.14% |
| EBITDA | 16.82% | -37.53% | 55.29% | -44.69% | -133.47% |
| EPS Basic | 49.43% | 34.21% | 56.13% | -29.46% | -133.77% |
| Normalized Basic EPS | 49.44% | 0.99% | 56.06% | -48.18% | -135.24% |
| EPS Diluted | 49.43% | 34.21% | 56.13% | -29.13% | -128.69% |
| Normalized Diluted EPS | 49.44% | 0.99% | 56.06% | -48.18% | -135.24% |
| Average Basic Shares Outstanding | 65.15% | 40.87% | 4.56% | 2.59% | 2.72% |
| Average Diluted Shares Outstanding | 65.15% | 40.87% | 4.56% | 2.59% | 2.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |